Clinical trial
Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST
NCT00331721 · PAION Deutschland GmbH, Industry · Terminated
Key facts
| NCT number | NCT00331721 |
|---|---|
| Title | Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST |
| Official title | A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalating Parallel-Group Study to Investigate the Tolerability of Enecadin (INN) in Acute Ischemic Stroke |
| Lead sponsor | PAION Deutschland GmbH, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stroke |
| Intervention type | Drug |
| Interventions | Enecadin, Placebo |
| Enrollment | 24 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | May 31, 2006 |
| Last update posted | May 22, 2008 |
| Countries | Austria, Belgium, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: